Fox Chase Cancer Center (FCCC) has a well-established strategic management planning process and formally produced five-year strategic and financial plans since 1985. These result in rolling five-year recruitment, resource development, and implementation plans which, after review by the Center's External Advisory Board, are approved by the Center Board of Directors. As part of the change in Center leadership during the current CCSG cycle, a comprehensive strategic planning process was launched under the direction of Associate CCSG Director for Academics J. Robert Beck, Wl.D. This is discussed fully in this section of the grant as well as in the "Overall Description of the Cancer Center" and "Developmental Funds" sections. The plan incorporates Center mission, vision, and values, as well as 13 Strategic Objectives. Targeted recruitment to each of the five CCSG Research Programs and a balance of individual investigation and team science are Critical Success Factors for the two Discovery Objectives in the Plan. No CCSG funds are requested for this planning effort. CCSG funds are requested for two aspects of our evaluation efforts. First, we seek support for our six external advisory boards, five of which provide review and advice to each of our scientific Programs. The sixth, the President's External Advisory Board, is comprised of national leaders in cancer research and NCI designated Cancer Center directors. These External Advisory Boards have been actively involved in our decisions to reconfigure existing or develop new Shared Facilities. They also provide advice on reconfiguration of existing CCSG Programs as well as the balance of team science and individual investigation. The second request is for partial support for our annual daylong Scientific Retreat where members from all five Programs and our clinical investigators meet and discuss opportunities for translational research as well as a broad-range of cancer-related scientific collaborations.

Public Health Relevance

Strategic planning is a necessary process to ensure future success and growth of cancer research. Evaluation both with internal and via External Advisory Boards is necessary to ensure that goals are achieved in an effective manner.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Research Institute of Fox Chase Cancer Center
United States
Zip Code
Austin, Steven R; Wong, Yu-Ning; Uzzo, Robert G et al. (2015) Why Summary Comorbidity Measures Such As the Charlson Comorbidity Index and Elixhauser Score Work. Med Care 53:e65-72
Bassi, Daniel E; Cenna, Jonathan; Zhang, Jirong et al. (2015) Enhanced aggressiveness of benzopyrene-induced squamous carcinomas in transgenic mice overexpressing the proprotein convertase PACE4 (PCSK6). Mol Carcinog 54:1122-31
Sherman, Kerry A; Miller, Suzanne M; Roussi, Pagona et al. (2015) Factors predicting adherence to risk management behaviors of women at increased risk for developing lymphedema. Support Care Cancer 23:61-9
Eytan, Esther; Wang, Kexi; Miniowitz-Shemtov, Shirly et al. (2014) Disassembly of mitotic checkpoint complexes by the joint action of the AAA-ATPase TRIP13 and p31(comet). Proc Natl Acad Sci U S A 111:12019-24
Johnson, Matthew E; Handorf, Elizabeth A; Martin, Jeffrey M et al. (2014) Postmastectomy radiation therapy for T3N0: a SEER analysis. Cancer 120:3569-74
Gabitova, Linara; Gorin, Andrey; Astsaturov, Igor (2014) Molecular pathways: sterols and receptor signaling in cancer. Clin Cancer Res 20:28-34
Silverman, Diana; Ruth, Karen; Sigurdson, Elin R et al. (2014) Skin involvement and breast cancer: are T4b lesions of all sizes created equal? J Am Coll Surg 219:534-44
Gupta, Sapna; Melnyk, Stepan B; Kruger, Warren D (2014) Cystathionine *-synthase-deficient mice thrive on a low-methionine diet. FASEB J 28:781-90
Simhan, Jay; Smaldone, Marc C; Egleston, Brian L et al. (2014) Nephron-sparing management vs radical nephroureterectomy for low- or moderate-grade, low-stage upper tract urothelial carcinoma. BJU Int 114:216-20
Gowrishankar, Banumathy; Ibragimova, Ilsiya; Zhou, Yan et al. (2014) MicroRNA expression signatures of stage, grade, and progression in clear cell RCC. Cancer Biol Ther 15:329-41

Showing the most recent 10 out of 475 publications